Incyte Corporation's performance in Q2 earnings has drawn attention from investors.
Incyte Corporation was highlighted in the Q2 earnings roundup for the biotechnology sector. The company's stock closed at US$113.20, reflecting a decline of 1.01% on the day. This decline is part of a broader trend, with the stock down 8.56% over the past week and 9.96% over the past month, though it has gained 12.53% year-to-date.
Investor takeaway: Investors should monitor Incyte's stock performance in light of its recent earnings report and market conditions.
Advertisement
Incyte Corporation
INCY.US
INCY.US
Incyte Corporation
WealthAwesomeMarket cap
$23.13B
P/E
14.5x
52W high
$132.60
52W low
$82.81
1W change
-8.56%
Beta
0.74
Analyst Price Targets
Based on 28 analysts covering INCY · as of Oct 6, 2026
Wall Street analysts forecast INCY stock price to rise 13.0% over the next 12 months.
Consensus
Buy3.71 / 5.00
Avg. Target
C$128.92
+13.0% Upside
Previously C$128.42 on Oct 5, 2026
Current Price
C$114.13
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on INCY's historical volatility
30-Day Vol
25.4%
Annualized
90-Day Vol
36.0%
Annualized
Trend (90d)
-9.4%
Annualized drift
90d Mean
C$110.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$112.86 | C$103.38 – C$123.22 |
| 60 trading days | C$111.61 | C$98.58 – C$126.36 |
| 90 trading days | C$110.37 | C$94.80 – C$128.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Incyte's Stock Declines 1.01% Amid Q2 Earnings Review
With a last close of US$113.20, Incyte's stock trades at a P/E ratio of 14.54 and has a market cap of approximately US$23.13 billion.
Bull case
Incyte's profit margin of 27.7% and return on equity of 30.7% suggest strong long-term growth potential.
Bear case
The recent decline in stock price raises concerns about its immediate outlook, especially since it is trading below its 50-day moving average of US$123.63.
Earnings Overview
Advertisement
Incyte Corporation's inclusion in the Q2 earnings roundup reveals a last closing price of US$113.20, which represents a 1.01% decrease in stock value for the day. This decline reflects investor concerns about the biotechnology sector's performance. The stock has seen a weekly decline of 8.56% and a monthly decline of 9.96%, suggesting a challenging environment as the market evaluates the potential of biotech investments.
Current Stock Performance
The performance of Incyte's stock is characterized by a trading volume of 1,254,999 shares, which is 1.20 times the 20-day average volume of 1,620,235 shares. Currently, Incyte is trading below its 50-day moving average of US$123.63, indicating a potential downward trend, while it is above its 200-day moving average of US$106.86. The stock is positioned at about 61% of its 52-week range, which spans from US$82.81 to US$132.60.
Looking Ahead
As analysts set an average target price of US$128.92 for Incyte, this implies a potential upside of 13.9% from its current trading level. Investors will need to keep an eye on upcoming earnings reports and market trends to gauge the company's trajectory. With a P/E ratio of 14.54 and a market cap of approximately US$23.13 billion, Incyte's valuation metrics will be crucial in determining its attractiveness in the biotechnology sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
